A study conducted at the Francis Crick Institute has discovered that Aspirin may be able to boost the effectiveness of cutting-edge cancer medicines that boost the immune system.
The study showed that skin, breast and bowel cancer cells were producing high levels of a chemical, called prostaglandin E2, that could dampen down the immune response and drugs like aspirin can prevent the production of prostaglandin E2.
We are very far off patients, all this is preclinical research in mouse models, what we would like to do now is set up a clinical trial to formally demonstrate this could happen in humans,” Prof Caetano Reis e Sousa, one of the researchers told BBC.
He added that “The findings are exciting in the context of renewed interest in immunotherapy, really everyone in oncology and immunology has become extremely excited.
“But what we’re finding is not a revolution, it’s an evolution [that could help us] try to achieve an even greater rate of remission.”